Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Vespireit prolonged-release tablets compared to Arlevert tablets in adults aged 18 to 65 with autonomic dysfunction syndrome accompanied by functional vertigo. This phase 4, open-label, randomized controlled trial investigates how these treatments impact symptoms related to vertigo and autonomic dysfunction. Participants will be randomly assigned to receive either Vespireit, 15 mg once daily in the morning with food, or Arlevert, 40 mg plus 20 mg three times daily with food. Both treatments are taken orally as whole tablets for 28 days. The study includes an initial treatment phase and a retreatment period, with careful monitoring throughout. During the study, participants will have multiple visits to assess changes in vertigo symptoms using the Mean Vertigo Score and Dizziness Handicap Inventory, as well as quality of life and anxiety levels. Researchers will track adverse events and therapy effectiveness through patient and physician evaluations. The study duration includes the initial 28-day treatment with follow-up visits extending through a retreatment period lasting up to 42 days.
Actively Recruiting
Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.